Description of the Webinar
The generation of robust evidence from well-designed, well-powered randomised trials is the conceptual underpinning of contemporary medicine. Nephritis affects more than half of patients with lupus during their disease course and has a substantial impact on prognosis. Randomised trials in lupus have addressed the role of agents in remission induction and maintenance. Recent interest has focussed on pathophysiological pathways and the associated development of biologics. This talk will provide an overview of recent randomised trials in lupus nephritis.
This webinar was held on Friday, October 14th, 2017 from 12PM - 1PM AEDT (Sydney/Melbourne time).
Those who missed the webinar can view the webinar recording below:
About the Facilitator
Meg Jardine -
A/Professor Meg Jardine is a clinical researcher at The George Institute for Global Health supported by a National Health & Medical Research Council and National Heart Foundation Fellowship. She is Head of George Clinical Renal Trials, Deputy Chair of the Australasian Kidney Trials Network and a nephrologist at Concord Repatriation General Hospital, a University of Sydney hospital. Her research investigates the progression and complications of kidney disease through epidemiological analyses of large scale datasets and the development and implementation of randomised clinical trials.